Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy
Pain
About this trial
This is an interventional prevention trial for Pain focused on measuring pain, retinal photocoagulation, potassium diclofenac
Eligibility Criteria
Inclusion Criteria:
- 1)high-risk proliferative diabetic retinopathy in both eyes
Exclusion Criteria:
- 1)history of prior laser treatment or vitrectomy; 2) allergy to non-steroidal anti-inflammatory drugs; 3) any condition affecting comprehension of VAS pain score test; 4) Contra-indications for diclofenac use such as pregnancy, bleeding disorders, asthma, or renal failure; 5) use of any analgesic drug for the last 24 hours.
Sites / Locations
- Ribeirão Preto School of Medicine Clinics Hospital - USP
Arms of the Study
Arm 1
Arm 2
Other
Other
Placebo first (scheme 2)
Diclofenac first (scheme 1)
scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye
scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye